Genentech Names Claudia Estrin Vice President, Decision Support and Commercial Innovation

Business Wire, Dec 19, 2000

Business Editors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 19, 2000

Genentech, Inc. (NYSE:DNA) today announced the appointment of Claudia Estrin to vice president, Decision Support and Commercial Innovation. Estrin will report directly to Myrtle Potter, executive vice president of Commercial Operations and chief operating officer.

"We are fortunate to have someone with Claudia's experience and reputation for driving business value to take on this increasingly important facet of Genentech's commercial organization," said Potter. "As Genentech continues to grow, so too will the demands upon our commercial teams. Claudia and her group will provide the technical tools to help meet this demand."

At Genentech, Estrin will serve on the Commercial Operating Committee and will be responsible for designing, sourcing and bringing into practice new decision support tools, capabilities and approaches that add to the commercial organization's ability to make better resource and investment decisions.

Estrin, 48, most recently held the position of executive vice president, Customer Operations and Corporate Administration at Boron, LePore & Associates, Inc., an outsource pharmaceutical sales and marketing organization. Prior to that, Estrin worked at Bristol-Myers Squibb as director, Strategic Marketing and Media. Estrin also worked for twelve years at Merck, where she held positions in sales, marketing and operations.

Estrin holds a Bachelor of Science degree in Occupational Therapy from Western Michigan University.

Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Fourteen of the currently approved products of biotechnology stem from Genentech science. Genentech markets nine products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.